Oncology Pharmacy Specialty Review Course for Recertification, Workbook Chapters + RECERT EXAM (Cert # L219098)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 04/14/2021
Content Release Date: 04/28/2021
Expiration Date: 04/12/2022
Activity Type: Application-based
CE Credits: 25.75 hours (ACPE only)
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists

The American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in oncology pharmacy.

Activity Overview

This course is intended for BCOPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will: 

  • Reviewing pertinent clinical topics and practice skills
  • Listing valuable references for further study

This online course consists of 20 activities (see table below) and provides up to 25.75 hours of continuing pharmacy education credit and/or recertification credit.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 25.75 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Oncology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/onc-review 

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS. 

* Please note: Review Course for Recertification may only be completed for recertification credit up to three times, in nonconsecutive years, during the 7-year recertification cycle.

Learning Module

ACPE Number

Credit Hours

*Assessment Pass Point

Breast Cancer

0204-9999-21-922-H01-P

2.50

76%

Gynecologic Malignancies

0204-9999-21-914-H01-P

1.00

Prostate Cancer

0204-9999-21-916-H01-P

1.00

Pediatric Malignancies and Supportive Care

0204-9999-21-926-H01-P

1.25

 

Group 1 Assessment

5.75

 

Upper Gastrointestinal and Hepatocellular Carcinomas

0204-9999-21-924-H01-P

0.75

76%

Bladder, Renal Cell, and Testicular Cancers

0204-9999-21-929-H01-P

1.00

Melanoma and Non-Melanoma Skin Cancers

0204-9999-21-915-H01-P

1.00

Research Design, Statistics, and Evaluating Oncology Literature

0204-9999-21-912-H04-P

2.00

 

Group 2 Assessment

4.75

 

Adult Acute Leukemias and Myelodysplastic Syndromes

0204-9999-21-928-H01-P

1.50

78%

Lymphomas

0204-9999-21-925-H01-P

1.25

Chronic Leukemias

0204-9999-21-917-H01-P

1.50

Hematopoietic Stem Cell Transplantation

0204-9999-21-921-H01-P

1.25

 

Group 3 Assessment

5.50

 

Lung Cancer

0204-9999-21-923-H01-P

1.50

77%

Lower Gastrointestinal and Pancreatic Cancers

0204-9999-21-927-H01-P

1.25

Head, Neck and Adult Central Nervous System (CNS) Malignancies

0204-9999-21-930-H01-P

1.00

Cancer-related Infectious Diseases

0204-9999-21-931-H01-P

1.00

 

Group 4 Assessment

4.75

 

Oncology Practice Management

0204-9999-21-920-H04-P

2.00

77%

Multiple Myeloma

0204-9999-21-918-H01-P

1.50

Adult Sarcoma

0204-9999-21-919-H01-P

0.75

Pharmacogenomics in Oncology

0204-9999-21-913-H01-P

0.75

 

Group 5 Assessment

5.00

 

Learning Objectives

At the end of the presentations, the pharmacist should be able to: 

Breast Cancer
ACPE #: 0204-9999-21-922-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver.
  • Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
  • Identify appropriate diagnostic and prognostic tests related to breast cancer.
  • Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening). 

Gynecologic Malignancies
ACPE #: 0204-9999-21-914-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy.
  • Discuss short and long-term goals, including post-therapy and survivorship, for a patient with a gynecologic malignancy and her caregiver.
  • Compare and contrast the efficacy and toxicity of different routes of drug administration, including IP chemotherapy, in the treatment of ovarian cancer.
  • Select relevant information and provide guidance for the public regarding gynecologic malignancy‐related issues (e.g., risk factors, prevention and screening). 

Prostate Cancer
ACPE #: 0204-9999-21-916-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
  • Identify appropriate diagnostic, prognostic, and monitoring tests for a patient with prostate cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
  • Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening). 

Pediatric Malignancies and Supportive Care
ACPE #: 0204-9999-21-926-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
  • Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a pediatric patient with cancer.
  • Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality. 

Upper Gastrointestinal and Hepatocellular Carcinomas
ACPE #: 0204-9999-21-924-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
  • Develop an appropriate plan for preventing, monitoring, and treating radiation recall and other complications of radiation therapy. 

Bladder, Renal Cell, and Testicular Cancers
ACPE #: 0204-9999-21-929-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal, or testicular cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal, or testicular cancer and his or her caregiver
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors. 

Melanoma and Non-Melanoma Skin Cancers
ACPE #: 0204-9999-21-915-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
  • Identify relevant cancer-related molecular biology testing for a patient with melanoma.
  • Discuss short-term and long-term treatment goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
  • Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors. 

Research Design, Statistics, and Evaluating Oncology Literature
ACPE #: 0204-9999-21-912-H04-P

  • Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population.
  • Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).
  • Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
  • Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study. 

Adult Acute Leukemias and Myelodysplastic Syndromes
ACPE #: 0204-9999-21-928-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic syndrome.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic syndrome.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.
  • Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in an adult based on genomic test results. 

Lymphomas
ACPE #: 0204-9999-21-925-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation. 

Chronic Leukemias
ACPE #: 0204-9999-21-917-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with chronic leukemia.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing in a patient with chronic leukemia.
  • Determine appropriate pharmacotherapy based on genomic test results in a patient with chronic leukemia.
  • Develop an appropriate plan for preventing, monitoring, and treating infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers. 

Hematopoietic Stem Cell Transplantation
ACPE #: 0204-9999-21-921-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HSCT).
  • Apply appropriate strategies to prevent toxicity from chemotherapy agents employed in HSCT conditioning regimens.
  • Create a plan for prevention and management of acute and chronic graft‐versus‐host disease (GVHD) using appropriate systemic and ancillary therapies.
  • Discuss short‐ and long‐term treatment goals, including post-therapy and survivorship, with the patient undergoing HSCT and his or her caregiver. 

Lung Cancer
ACPE #: 0204-9999-21-923-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
  • Identify relevant cancer-related molecular biology testing for a patient with lung cancer.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lung cancer.
  • Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.
  • Develop a prevention and management strategy for chemotherapy-induced nausea and vomiting for patients with any type of cancer. 

Lower Gastrointestinal and Pancreatic Cancers
ACPE #: 0204-9999-21-927-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lower GI or pancreatic cancers.
  • Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors. 

Head, Neck and Adult Central Nervous System (CNS) Malignancies
ACPE #: 0204-9999-21-930-H01-P

  • Design an appropriate patient-specific treatment, management and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS) malignancies, or thyroid cancers.
  • Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, and screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cachexia, mucositis, and xerostomia. 

Cancer-related Infectious Diseases
ACPE #: 0204-9999-21-931-H01-P

  • Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during and following cancer treatment based on current guidelines for treating cancer-related infectious diseases.
  • Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver. 

Oncology Practice Management
ACPE #: 0204-9999-21-920-H04-P

  • Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for safe handling, administration, and disposal of hazardous drugs.
  • Select quality-improvement activities that enhance the safety and effectiveness of the medication-use process in oncology patient care.
  • Explain national accreditation and federal regulatory requirements for the care of cancer patients receiving chemotherapy or other hazardous drugs.
  • Explain medication reimbursement and patient assistance programs to optimize drug availability for oncology patients.
  • Evaluate policies and procedures related to conducting research involving investigational drugs, including drug management in patients with cancer. 

Multiple Myeloma
ACPE #: 0204-9999-21-918-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
  • Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
  • Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases in multiple myeloma patients and thromboembolism, hypercalcemia of malignancy, and spinal cord compression in all oncology patients. 

Adult Sarcoma
ACPE #: 0204-9999-21-919-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
  • Adjust treatment and monitoring plans as needed based on the tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
  • Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer, including neurotoxicity from ifosfamide and hemorrhagic cystitis. 

Pharmacogenomics in Oncology
ACPE #: 0204-9999-21-913-H01-P

  • Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques.
  • Apply the results from somatic genetic testing into therapy recommendations based on prognostic, predictive and patient characteristics.
  • Recognize the place in therapeutic decision making for companion diagnostic testing. 

Faculty 

Jessica Auten, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist, Acute Care Malignant Hematology
UNC Medical Center
Chapel Hill, North Carolina 

John Bossaer, Pharm.D., BCPS, BCOP
Associate Professor
Gatton College of Pharmacy at ETSU
Johnson City, Tennessee 

Courtney Cavalieri, Pharm.D., BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah 

Brette Conliffe, Pharm.D., BCOP
Clinical Oncology Pharmacist
University of Louisville Health/Brown Cancer Center
Louisville, Kentucky 

Karen Fancher, Pharm.D., BCOP*
Associate Professor of Pharmacy Practice / Clinical Pharmacy Specialist - Oncology
Dusquesne University School of Pharmacy / University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Christopher Fausel, Pharm.D., M.H.A., BCOP
Clinical Manager - Oncology Pharmacy / Chairman
Indiana University Health / Hoosier Cancer Research Network
Indianapolis, Indiana 

Kelly Fritz, Pharm.D., BCOP
Oncology Clinical Coordinator
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah 

Lauren Ice, Pharm.D., BCOP, BCPS
Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan 

Elyse MacDonald, Pharm.D., M.S., BCPS
Assistant Director, Pharmacy Services, Investigational Drug Service
Stanford Health Care
Palo Alto, California 

Janelle Mann, Pharm.D., BCOP
Clinical Oncology Pharmacist / Manager, Clinical Pharmacy Services
Alvin J. Siteman Cancer Center / Washington University School of Medicine in St. Louis
St. Louis, Missouri 

Anthony Perissinotti, Pharm.D., BCOP
Hematology Clinical Pharmacist Specialist
University of Michigan - Michigan Medicine
Ann Arbor, Michigan 

Tim Peterson, Pharm.D., BCOP
Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York 

Danielle Roman, Pharm.D., BCOP*
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania 

Christine Walko, Pharm.D., BCOP, FCCP*
Associate Member, Personalized Medicine Specialist / Associate Professor, Department of Oncologic Sciences
DeBartolo Family Personalized Medicine Institute
H. Lee Moffitt Cancer Center / USF Morsani College of Medicine
Tampa, Florida 

Jennifer Young, Pharm.D., BCOP
Clinical Pharmacy Specialist - Pediatric Oncology
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 

*Content Matter Experts

Reviewers

Courtney Alexander, Pharm.D., BCPS, BCOP
Jaime Anderson, Pharm.D., BCOP, CMQ
Carrie Beckman, Pharm.D., BCPS, BCOP
Laura Bobolts, Pharm.D., BCOP
Salvatore Bottiglieri, Pharm.D., BCOP
Theresa Brown, Pharm.D. BCOP CPP
Joseph Bubalo, Pharm.D., BCOP, BCPS
Ryan Bycroft, Pharm.D., BCOP
Brandon Chang, Pharm.D., BCPS, BCOP
Jill Comeau, Pharm.D., BCOP
Vanessa Copeland, Pharm.D., BCOP
Wendy Covert, Pharm.D., BCOP
Sara DeHoll, Pharm.D., BCOP
Bryna  Delman Ewachiw, Pharm.D., BCOP
Seema Ganatra, Pharm.D., BCPS, BCOP
Sarah Gifford, Pharm.D., BCOP
Sean Green, Pharm.D., BCOP
Alyssa Heiden, Pharm.D., BCOP
Hansen Ho, Pharm.D., BCOP
Mitchell Hughes, Pharm.D., BCPS, BCOP
Ashley Johns, Pharm.D., M.S., BCOP, BCPS
Lindsay Kaster, Pharm.D., BCOP
Jodi Lech, Pharm.D., BCOP
Matthew Lei, Pharm.D., BCOP
Samantha Luk, Pharm.D., BCOP
Morgan Mace, Pharm.D., BCOP
Lisa Modelevsky, Pharm.D., BCOP
Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Nancy Nix, Pharm.D., BCPS, BCOP
Terry  Pak, Pharm.D., BCOP
Jeremy Pappacena, Pharm.D., BCOP
Seon Jo Park, Pharm.D., BCOP
Jennifer Piccolo, Pharm.D., BCOP
Melvin Rivera, Pharm.D., BCOP
Shreya Shah, Pharm.D., BCOP
Anne Spengler, Pharm.D., BCOP
Zane Waite, Pharm.D., BCOP
Robert Wilkinson, Pharm.D., M.S., BCOP, BCPS
Lily Yan, Pharm.D., BCOP
Mark Zangardi, Pharm.D., BCOP 

Field Testers

Zeinab Abdelwhab, BCOP
Nelly Adel, Pharm.D, BCOP, BCPS
Courtney Alexander, Pharm.D., BCPS, BCOP
Jaime Anderson, Pharm.D., BCOP, CMQ
Sarah Anderson, Pharm.D., BCOP
Jonathan Angus, Pharm.D., BCOP
Kellye Aschmeyer, Pharm.D., BCOP
Cynthia Barlow, B.S., Pharm.D., BCOP, BCPS
Mollie Beck, Pharm.D., BCOP
Carrie Beckman, Pharm.D., BCPS, BCOP
Denae Beckman, Pharm.D., BCOP
Philip Benoit, Pharm.D., BCOP
Laura Bobolts, Pharm.D., BCOP
Salvatore Bottiglieri, Pharm.D., BCOP
Janet Bramell, Pharm.D., BCPS, BCOP
Theresa Brown, Pharm.D., BCOP, CPP
Joseph Bubalo, Pharm.D., BCPS, BCOP
Phyllis Bull, Pharm.D., BCOP
Yuliya Byakina, Pharm.D., BCOP
Ryan Bycroft, Pharm.D., BCOP
Natalia Cadavid, Pharm.D., BCOP
Robert Cade, Pharm.D., BCOP
Cathy Cao, Pharm.D., BCOP
Robert Carr, Pharm.D., BCPS, BCOP
Caroline Carson, Pharm.D., BCOP
Kelly Leigh Casey, Pharm.D., BCOP
Mark Chamberlain, B.S.Pharm, Pharm.D., BCOP
Ansley Chambers, Pharm.D, BCOP
Betty Chan, Pharm.D., BCOP
Cara Chang, Pharm.D., BCOP, MS
Alexis Chapman, Pharm.D., BCOP
Sheree Chen, Pharm.D., BCOP
Shu Yi Chen, BCOP
Berrie Child, Pharm.D., BCOP
Kelly Chillari, Pharm.D., BCOP
Nicholas Chow, Pharm.D.,BCOP
Mitzi Christ, Pharm.D., BCOP
Stefanie Clark, Pharm.D., BCOP
Aimee Cloud, Pharm.D., BCOP
Jennifer Collins, Pharm.D., BCOP
Jill Comeau, Pharm.D., BCOP
Brette Conliffe, Pharm.D., BCOP
Vanessa Copeland, Pharm.D., BCOP
Wendy Covert, Pharm.D., BCOP
Phuong Dao, Pharm.D., BCOP
Laura Darland, Pharm.D., BCOP
Kathy Dasse, Pharm.D., BCOP
Sara deHoll, Pharm.D., BCOP
Bryna Delman Ewachiw, Pharm.D.. BCOP
Thu Doan, Pharm.D., BCOP
Jean Doh, Pharm.D., BCOP
Robert Dowd, B.S., Pharm.D., BCOP
Michelle Dowhan, B.S.c.Pharm., BCOP
Ashley Drolshagen, Pharm.D., BCPS, BCOP
Megan Duperreault, Pharm.D., BCOP
Linda Elnazir, Pharm.D, BCPS, BCOP
John Elsasser, Pharm.D., BCPS, BCOP
Jason Ernstberger, Pharm.D., BCOP
Jennifer Espiritu, Pharm.D., BCOP
Stephanie Evangelisti, Pharm.D., M.S., BCOP
Bryna Ewachiw, Pharm.D., BCOP
Karen Fancher, Pharm.D., BCOP
Tate Feeney, Pharm.D., BCOP
Lora Ferguson, Pharm.D., BCOP
Melika Fini, Pharm.D., BCOP
Stephen Ford, Pharm.D., BCOP
Seema Ganatra, Pharm.D., BCPS, BCOP
Peter Gargano, Pharm.D., BCOP
Frank Gentile, Pharm.D., BCOP
Muoi Gi, Pharm.D., BCPS, BCOP
Anna Gibson, B.S., Pharm.D., BCOP
Andrew Gifford, Pharm.D, BCOP
Sarah Gifford, Pharm.D.,  BCOP
Pilar Gonzalez, Pharm D., BCOP
Sara Gordon, Pharm.D., BCOP
Sean Green, Pharm.D., BCOP
Kyle Grose, Pharm.D., BCPS, BCOP
Katherine Guglielmino, Pharm.D., BCPS, BCOP
Carolyn Hall, Pharm.D., BCOP
Cara Harshberger, Pharm.D., BCOP
Deborah Hass, Pharm.D, BCOP, BCPS
Elisabeth Hebert, Pharm.B., BCOP
Alyssa Heiden, Pharm.D., BCOP
Kristi Herald, Pharm.D., BCPS, BCOP
Yvonne Hewett, Pharm.D., BCOP
Erin Hickey, Pharm.D., BCOP
Meredith Higley, Pharm.D., BCOP
Annie Ho, Pharm.D., BCOP
Hansen Ho, Pharm.D., BCOP
Paul Hoffmann, R.Ph., BCOP
Candace Hooper, Pharm.D., BCPS, BCOP
Jerline Hsin, Pharm.D., BCPS, BCOP
Ivan Huang, Pharm.D., BCOP
Caren Hughes, Pharm.D., M.B.A., BCOP
Mitchell Hughes, Pharm.D., BCPS, BCOP
Ying Ci (Wendy) Hui, Pharm.D., BCOP
Sam JacoB.S.on, Pharm.D., BCOP
Anna Jan, Pharm.D., BCOP
Lisa Janssen Carlson, Pharm.D., BCOP
Austin Jenkins, Pharm.D., BCOP
Ashley Johns, Pharm.D., M.S., BCOP, BCPS
Amy Kamien, Pharm.D., BCOP
Shraddha Kansagra, Pharm.D., BCOP
Lindsay Kaster, Pharm.D., BCOP
Stephen Kaurala, Pharm.D., BCOP
Melanie Kay, Pharm.D., BCOP, BCPS
Elle Kim, R.Ph., BCPS, BCOP
Tracy Joy King, Pharm.D., BCOP, BCPS
Kimberley Kolb, RPh, BCOP
Nirachorn Kuchonthara, B.S.c Pharm, BCOP, BCNSP
David Kwasny, Pharm.D., BCOP
Leslie LaMontagne, Pharm.D., BCOP
Jodi Lech, Pharm.D., BCOP
Chung-Shien Lee, Pharm.D., BCPS, BCOP
Whitney Lewis, Pharm.D., BCOP
Suwicha Limvorasak, Pharm.D., BCOP
Pohung Lin, Pharm.D., BCOP, BCPS
Linda Linderbeck, Pharm.D.
Tristan Lindfelt, Pharm.D., BCPS, BCOP
Jan Lowe, Pharm.D., BCOP
Samantha Luk, Pharm.D., BCOP
Morgan Mace, Pharm.D., BCOP
Claire Mach, Pharm.D., BCOP
Jonathan Malara, Pharm.D., BCOP
Eric Margallo, Pharm.D., BCOP
Jennifer Martin, Pharm.D., BCOP
Sam Martinez, Pharm.D., BCOP, BCPS
Stephanie Matta, Pharm.D., BCOP
Ruth Maxson, R.Ph., BCOP
Lilian May, Pharm.D., BCPS, BCOP
Lauren McBride, Pharm.D., BCOP
Margaret McCallen, B.S., Pharm.D.,  BCOP
Tetyana Melnyk, Pharm.D., BCOP
Lisa Modelevsky, Pharm.D., BCOP
Kureisha Mohamed, Pharm.D., BCOP
Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Sherry Mori Vogt, Pharm.D., BCOP
Megan Mullalley, Pharm.D. BCPS BCOP
Jessica Muth, Pharm.D., BCPS, BCOP
Victoria Nachar, Pharm.D., BCOP
Sindhu Nair, Pharm.D., BCOP
Bao Nguyen, Pharm.D., BCPS, BCOP
Charles Ni, Pharm.D.., BCPS, BCOP
Nancy Nix, Pharm.D., BCPS, BCOP
Jeanne Noe, Pharm.D., BCOP
David Nowinski, Pharm.D, BCOP
Chukwuemeka Nzelibe, Pharm.D., BCOP, M.B.A.
Shan Connor, Pharm.D., BCOP
Yevgeny Okumyansky, Pharm.D.,BCPS,BCOP
Laura Olson, R.Ph., BCOP, BCPS
Nabil Elhadi Omar, R.Ph., B.S.c Pharm, BCOP, Pharm.D.
Diwura Owolabi-Odukoya, Pharm.D., BCOP
Carolyn Oxencis, Pharm.D., BCOP
Marie-Therese Oyalowo, Pharm.D., BCOP, RN
Terry Pak, Pharm.D., BCOP
Jeremy Pappacena, Pharm.D., BCOP
Jooyoung Park, Pharm.D., BCOP
Seon Jo Park, Pharm.D.,BCOP
Kinjal Patel, Pharm.D., BCOP
Amanda Pawlenty, Pharm.D., BCOP
Amanda Peffer, Pharm.D., BCOP
Annie Pellegrino, Pharm.D., BCOP
Megan Pereira, BCOP
David Pham, Pharm.D., BCOP
Jennie Piccolo, Pharm.D., BCOP
Megan Pinter, M.A., Pharm.D., BCOP
Anuradha Pradhan, BCOP
Krishna Rajasekar, B.Pharm., BCOP
Mohammad Rattu, Pharm.D., BCOP, BCPS, BCGP
Leslie Ray, Pharm.D., BCOP
Angela Raymond, Pharm.D., BCOP
David Reeves, Pharm.D., BCOP
Forrest Ridgway, Pharm.D., BCPS, BCOP
Amy Riedel, Pharm.D., APh, BCPS, BCOP
Melvin Rivera, Pharm.D., BCOP
Aouicha Rostane, R.Ph., BCOP\
Kristen Rychalsky, Pharm.D., BCPS, BCOP
Eric Sansocie, Pharm.D., BCOP
Megan Saraceni, Pharm.D., BCOP
Matthew Saylor, Pharm.D., BCOP
Hope Schenk, Pharm.D., BCOP
Danielle Schlafer, Pharm.D., BCOP
David Schoenbaechler, Pharm.D., BCOP
Bryan Schuler, Pharm.D., BCOP
Bridget Scullion, Pharm.D., BCOP
Brian Seiki, Pharm.D., BCOP
Shreya Shah, Pharm.D., BCOP
Meenakshi Shelat, Pharm.D., BCOP
Anna Shook, Pharm.D., BCPS, BCOP
Jennifer Showalter, Pharm.D., BCPS, BCOP
En Hui Phebe Si, Pharm.D.,  BCOP
Beng yi Sia, BCPS, BCOP, BSC.Pharm, MSC.Pharm.
Jim Siderov, Bpharm, MC.Pharm., BCOP
Shayna Simon, Pharm.D., BCOP
Amanda Sirisaengtaksin, Pharm.D., BCOP
Sunao Slayton, Pharm.D., BCOP
Katelyn Sommerer, Pharm.D., M.S., BCOP
Anne Spengler, Pharm.D., BCOP
Carol Stadler, B.S.Pharm, Pharm.D., BCOP
Alison Stebbings, Pharm.D., BCOP
Connie Suen, Pharm.D.
Thomas Sullivan, Pharm.D., BCOP
Wai Tak Vince Sung, Pharm.D., BCOP
Audrea Szabatura, Pharm.D., BCOP
Amy Tam, Pharm.D., BCOP
Kelly Tammaro, Pharm.D., BCOP
Kate Taucher, Pharm.D., M.H.A., BCOP
Lisa Thompson, Pharm.D., BCOP
Nidia Torres Pena, Pharm.D., BCOP
Caroline Townley, Pharm.D., BCOP
Carissa Treptow, Pharm.D., BCOP
Viv Tsang, Pharm.D., BCOP, BCPS
David Turberville, Pharm.D., BCOP
Tina Tweedley, Pharm.D., BCOP
Sorana Ursu, Pharm.D., BCOP
Amy VanGalder, Pharm.D., BCOP
David Veasey, Pharm.D., BCOP
Cory Vela, Pharm.D., BCOP
Zane Waite, Pharm. D., BCOP
Paul Wallace, Pharm.D., BCOP
Mary Walters, Pharm.D., BCOP
Stephanie Willenbring, Pharm.D., M.P.H., BCOP
Reba Williams, R.Ph., BCOP
Jason Wing, Pharm.D., BCOP
Doris Wong, Pharm.D., BCPS, BCOP
Chen Xu, Ph.D., BCOP
Kendall Yake, Pharm.D., BCOP
Lily Yan, Pharm.D., BCOP
Erin Yeung, Pharm.D., BCPS, BCOP
Barbara Yim, Pharm.D., BCOP\
Wao Chung Yiu, Mpharm., BCOP
Carolnn Yong, Pharm.D, BCPS, BCOP
Abubakr Yousif, MSc., BCOP
Mark Zangardi, Pharm.D., BCOP
Junle Zhou, Pharm.D., BCOP
Jamie Ziggas, Pharm.D., BCOP

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Karen Fancher is Consultant, AstraZeneca, LP; Consultant, Merck & Co. 

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP.